ConvaTec Group has appointed Dr Regina Benjamin and Margaret Ewing as non-executive directors with immediate effect.
Benjamin was United States surgeon general from 2009 – 2013 and is currently a non-executive director of Diplomat Pharmacy, Kaiser Foundation Hospitals and Health Plan, and Ascension Hospital System. She is a former non-executive director of Alere.
From 1992-2004 she served on the board of the Medical Association of Alabama, and in 1995, became the first young physician to be elected to the American Medical Association Board of Trustees. In 2008, she chaired the Federation of State Medical Licensing Boards.
Benjamin is CEO and practising physician at the Bayou La Batre Rural Health Clinic in Alabama, which she founded in 1990 and holds an endowed chair in Public Health Sciences at Xavier University of Louisiana. She will immediately join the corporate responsibility committee.
Ewing is currently a trustee of the board and chairman of the finance and audit committee of Great Ormond Street Hospital Children’s Charity. She is also the independent external member of the audit committee of the Lawn Tennis Association.
Ewing was previously a non-executive director of Standard Chartered, Whitbread and the Confederation of British Industry and the independent external member of the audit committee of John Lewis Partnership.
She was a corporate finance partner of Deloitte LLP between 1987-1999, returning to Deloitte in 2007 as a senior partner and retiring from the firm in 2012.
During the period 2007-2012 Mrs Ewing was vice-chairman and a member of the firm’s executive committee and the board, senior partner of the London practice and latterly managing partner for public policy, quality and risk.
Ewing was group chief financial officer of Trinity Mirror from 2000-2002 and of BAA plc from 2002-2006. She was also a member of the financial reporting review panel between 2011-2014. She will immediately join the audit and risk committee and corporate responsibility committee.
It was previously announced that Dr Raj Shah would be leaving the board of ConvaTec on 8 September 2017 following the reduction by Nordic Capital of its shareholding in the company.
Dr Ros Rivaz, who was appointed a non-executive director of the company on 21 June , will immediately join the nominations and remuneration committees in place of Shah.
Chairman Sir Christopher Gent said: “I am delighted to announce two appointments of individuals who bring a wealth of experience and knowledge to the Board.
“Also with the appointments of Regina and Margaret, we have fulfilled our promise to shareholders that we would appoint a Board which would comprise a majority of independent Directors and which would reflect the requirements and advantages of gender diversity.
“We look forward to benefiting from their contribution to the future success of the Company.”
Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance (AMR) expertise. Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.
Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m). Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).
Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September. According to the Swiss Contract Development and Manufacturing Organization (CDMO), the separation is by mutual agreement.